Abstract
INTRODUCTION
Colon cancer is a common malignancy of the digestive tract. Studies have shown that the incidence of colon cancer is ≥ 0.005% [1] and that the incidence has continued to trend upwards in recent years because of risk factors such as diet and smoking [2, 3] .
Basic cancer research has shown that changes in the levels of certain molecules affect tumor cell proli feration and differentiation, which in turn affect the development and progression of malignant tumors [4] . Annexin A5, first isolated from human placenta, was found to bind to phosphatidylserine in a calcium dependent manner [5, 6] . In the present study, 93
patients with colon cancer who were treated at our hospital between February 2013 and March 2016 were included to investigate the expression of annexin A5 in serum and in cancer tissues, with an aim to investigate its clinical significance.
MATERIALS AND METHODS

General information
Ninetythree patients with colon cancer (observation group) who were treated at our hospital between February 2013 and March 2016 were included in this study. The inclusion criteria were as follows: (1) pathologically confirmed colon cancer; (2) complete clinical and pathological data; and (3) being willing to provide informed consent. The exclusion criterion was incomplete clinical or pathological data. Forty healthy individuals who underwent a routine health checkup at our hospital were included as controls. No significant difference was observed with respect to age or gender between the two groups ( Table 1) .
Detection of serum level of annexin A5
A fasting venous blood sample was collected from each subject in the morning and centrifuged at 10000 r/min to separate the serum, which was then stored at 20 ℃ and tested within one week to determine the annexin A5 level. The Roche automated biochemical analyzer E170 module was used for testing, and the assay kit was purchased from Shanghai Taikang Biotechnology Co., Ltd. The assay was performed according to the instructions given in the package insert. Control serum or standard was included with the kit.
Immunohistochemistry
Paraffin sections were deparaffinized, rehydrated, and cut into 3 mm sections. The sections were incubated in 3% H2O2 at room temperature for 5 min, rinsed with deionized water (3 min × 3 times), blocked with 10% milk protein (1 g protein in 100 mL of purified water), and incubated at room temperature for 5 min. Next, the sections were incubated with a mouse anti annexin A5 antibody (Nanjing Biyuntian Biotechnology Co., Ltd.) for 2 h at 37 ℃, followed by a PBS wash (5 min × 3 times). Then, the slides were incubated with a horseradish peroxidaselabeled rabbit secondary antibody (Roche) for 30 min at 37 ℃, followed by a PBS wash (5 min × 3 times). After that, the slides were incubated with NBT/BCIP reagent, which was used to develop the reaction, for 5 min. Finally, the sections were counterstained, dehydrated, cleared, mounted, and observed under an OLIPICS microscope (Shanghai Precision Instrument Co., Ltd). All the req uired reagents were purchased from Nanjing Taikang Biotechnology Co., Ltd.
Evaluation criteria for immunohistochemical staining
Immunohistochemical staining was considered positive if yellow granules were present in the cytoplasm of tumor cells or stromal cells. The staining intensity was graded as follows: 0, no staining; 1, light yellow; 2, yellow; and 3, brown. The percentage of positive cells was scored as follows: 0, < 5%; 1, 5% to 24%; 2, 25% to 50%; 3, 51% to 74%; and 4, and ≥ 75%. The product of the staining intensity and the percentage of positive cells was either < 2 (negative) or ≥ 2 (positive). 
Statistical analysis
RESULTS
Annexin A5 expression in cancer tissue
No significant difference was observed in the positive expression rates of annexin A5 among patients of different ages or genders, or those with different tumor diameters. Moreover, 79.31% of the patients with lymph node metastasis expressed annexin A5, which was significantly higher than the percentage of patients without lymph node metastasis (P < 0.05); 86.96% of the patients with stage Ⅲ to Ⅳ disease expressed annexin A5, which was significantly higher than the percentage of patients with stage Ⅰ to Ⅱ disease (P < 0.05) ( Table 2) .
Serum levels of annexin A5 in the two groups
The serum level of annexin A5 was significantly higher in the observation group than in the control group (P < 0.05) ( Table 3) .
Correlation between serum level of annexin A5 and expression of annexin A5 in tumor tissue
The serum level of annexin A5 was 0.215 ± 0.044 ng/mL in patients whose colon tumors were positive for annexin A5 expression, which was significantly higher than the corresponding value in patients whose colon tumors were negative for annexin A5 (0.180 ± 0.021 ng/mL) (t = 4.599, P < 0.05). A Spearman rank correlation analysis showed that the serum level of annexin A5 was related to the expression of annexin A5 in tumor tissues (r = 0.312, P < 0.05).
Diagnostic value of serum level of annexin A5
The ROC curve for the serum level of annexin A5 in the diagnosis of colon cancer showed an area under the curve of 0.732 (P < 0.05). At a cutoff value of 0.148 ng/mL, the sensitivity was 83.90%, and the specificity was 57.50% ( Figure 1 ).
DISCUSSION
Changes in diet, excessive alcohol consumption, and genetic susceptibility factors promote the development and progression of colon cancer. In particular, among elderly male smokers aged 45 or older, the incidence of colon cancer is 0.005% or higher and has continued to trend upwards in recent years [7, 8] . For colon cancer, the incidence of early metastasis is high, which results in poor patient outcomes: the five years survival rate is < 35%, and the median survival time is < 32 mo [911] . Studies on the genetic and biological mechanisms of the development and progression of colon cancer may provide new targets for immune therapy or strategies of comprehensive biological therapy for colon cancer [12, 13] . Molecular changes play an important regulatory role in the development of malignant tumors. Cell surface Connexins or membrane proteins can induce the trans cription initiation activity of downstream oncogenes, which promotes aberrant activation of the cell cycle in colonic epithelial cells and leads to excessive proliferation of cancer cells [14] . Accumulating experimental data indicate that phosphatidylserine exposition is associated with apoptosis and other cell death programs [1517] , which renders it an attractive target in imaging overall cell death. Annexin A5 is identified in blood vessel as a blood anticoagulation factor and it builds voltagedependent calcium channel in phosphatidylserine bilayers [18, 19] . Corsten et al [20] showed that through binding with strong affinity to phosphatidylserine, annexin A5 offers an interesting opportunity for visualization of aggregate 
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cell death [21, 22] , thus providing a fit benchmark for in vivo monitoring of anticancer treatment [2326] . Recently, annexin A5 has been reported as a new mediator of cisplatininduced apoptosis by inducing voltage dependent anion channel oligomerization in human kidney epithelial cells [27, 28] . Annexin A5 forms N6
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In this study, immunohistochemical staining showed significantly high expression of annexin A5 in colon cancer tissue and demonstrated that the positive expression rate of annexin A5 was significantly higher in patients with lymph node metastasis than in those without. This suggests that annexin A5 may play a role in the promotion of the invasion of lymph nodes by colon cancer cells. Furthermore, approximately 80% of the patients with latestage (Ⅲ and Ⅳ) colon cancer expressed annexin A5, which was significantly higher than the percentage of patients with stage Ⅰ or Ⅱ disease, which suggests that annexin A5 significantly promotes the clinical progression and worsening of colon cancer. Annexin A5 induces the activation of second messengers in cancer cells, which promotes the production of cancer cell differentiation antigens, the proliferation and differentiation of colon cancer cells, and clinical progression.
In conclusion, annexin A5 is highly expressed in serum and tumor tissues of patients with colon cancer, and its expression is closely related to the clinical stage 
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